Financials

Financials — What the Numbers Say

GSFC reports in Indian rupees (₹). All figures are in ₹ crore (1 crore = 10 million) unless stated otherwise. Fiscal year ends 31 March (FY2025 = year ended 31 March 2025).

Financials in One Page

GSFC is a mid-size, integrated Indian fertilizer-and-chemicals PSU running at roughly ₹10,000 Cr (≈ US$1.2B) of annual revenue, with two distinct earnings layers: a price-controlled fertilizer business that earns thin, subsidy-dependent margins and an industrial chemicals book (caprolactam/nylon-6, melamine, methanol) that swings the P&L through the cycle. Reported revenue grew from ₹5,386 Cr in FY2014 to a ₹11,369 Cr peak in FY2023, then fell back to ₹9,534 Cr in FY2025; operating margin tracked the same arc — 9–11% normal, 14–15% at the FY2022–23 caprolactam peak, 6–7% in the FY2024–25 reset. The headline P&L looks acceptable, but earnings have not converted to cash for two straight years — FY2024 free cash flow was negative ₹508 Cr against a ₹564 Cr profit, and FY2025 was negative ₹296 Cr against ₹591 Cr — because subsidy receivables, inventory, and capex have moved against the company. The balance sheet is the saving grace: borrowings are effectively zero (₹2 Cr), investments are ₹5,055 Cr (~72% of market cap), and the stock trades at 0.56x book and 10x trailing earnings — cheap on the surface, but the discount reflects single-digit ROCE/ROE and PSU control. The single financial metric that matters next is operating cash flow — until CFO normalises, the cheap multiple is not actually cheap.

How to read this page: Section 2 covers what drives the income statement. Section 3 tests whether those earnings are real cash. Section 4 examines balance-sheet flexibility. Section 5 explains capital allocation. Section 6 (segment) is constrained by data limits. Section 7 builds the valuation case. Section 8 compares with peers. Section 9 is the watchlist.

---

2. Revenue, Margins, and Earnings Power

GSFC's earnings power is cyclical, not compounding. Revenue almost doubled in 12 years (₹5,386 Cr → ₹9,534 Cr), but reported net income peaked twice (FY2018 ₹474 Cr, FY2023 ₹1,266 Cr) and round-tripped both times. The single biggest swing factor is the caprolactam–nylon-6 spread (the gap between benzene/ammonia inputs and finished caprolactam prices) — that is what drove the FY2022–23 spike in operating margin from a 9% normal to 15%, and it is what collapsed margins back to 6–7% when global polymer demand cooled.

The shape of this chart is the whole story. Revenue trends gently upward; operating profit and net income are spiky. A multi-year average is more informative than any single year: 12-year mean revenue is ₹7,533 Cr, mean operating profit ₹698 Cr (9.3% margin), mean net income ₹512 Cr. Trailing-twelve-month numbers (revenue ₹10,235 Cr, operating profit ₹787 Cr, net income ₹693 Cr) sit above the long-run average, which is one reason the market treats reported earnings as "above mid-cycle."

The margin story is the chemicals story

Operating margin = profit from sale of goods, before interest, depreciation, tax and other income. It strips out one-off items and shows core profitability per rupee of revenue.

Two patterns matter. First, net margin holds up better than operating margin in down-cycles because GSFC's investment book throws off ~₹100–400 Cr of "other income" (interest, dividends, MTM) every year — in FY2020 that other income line (₹105 Cr) was 75% of net income. Second, the mid-cycle operating margin is 9–11%, not 14–15%. Underwriting GSFC at FY2022–23 margins is the most common analytical mistake.

Recent trajectory: stalled, not broken

Revenue has bottomed and is climbing — Q2 FY2026 hit ₹3,187 Cr, the highest non-Q3 revenue in the dataset and 21% above the year-ago quarter. Operating profit followed (₹337 Cr in Q2 FY2026 vs ₹284 Cr a year prior). Trailing-twelve-month operating profit of ₹787 Cr is recovering toward the long-run average but is well below the FY2023 peak of ₹1,588 Cr. The earnings inflection is real but modest. The fertilizer season (Q2: kharif, Q3: rabi) drives the seasonality: Q1 and Q4 are structurally weak.

---

3. Cash Flow and Earnings Quality

This is where the GSFC investment thesis is decided.

Free cash flow (FCF) is the cash a business generates after covering operating needs (working capital) and capital expenditures. If FCF persistently lags net income, reported earnings are not really turning into shareholder cash.

The 12-year cumulative numbers tell the truth. Cumulative net income FY2014–FY2025: ₹6,545 Cr. Cumulative free cash flow: ₹3,205 Cr. Cash conversion is roughly 49% — for every rupee of reported profit over the cycle, only ~49 paise turned into deployable cash. The shortfall went into working capital (mostly fertilizer-subsidy receivables that the Indian government settles with a lag) and into a step-up in capex.

Why FCF is negative in FY2024–25

Three things are happening simultaneously:

1. Cash from operations collapsed from ₹924 Cr (FY2023) to negative ₹268 Cr (FY2024) and recovered only to ₹83 Cr (FY2025). The bulk of the swing is working-capital absorption — inventory days rose from 70 to 89 over two years, and receivables timing has been choppy.
2. Capex stepped up. Capital expenditure averaged ₹250–350 Cr historically; in FY2024–25 it was higher (CWIP — capital work-in-progress — rose from ₹200 Cr to ₹690 Cr at FY25 close, signalling a project pipeline being built up).
3. Other income subsidised reported profit. Other income hit ₹385 Cr in FY2024 and ₹323 Cr in FY2025, ~50% of pretax profit. Strip it out and core operating profit / capex coverage looks much weaker.

FCF margin has been negative in 5 of 12 years. There is no consistent cash machine here — there is a business that occasionally throws off ₹1,500–1,800 Cr of cash (FY2014, FY2021) when working capital releases, and a business that occasionally absorbs ₹300–500 Cr (FY2016, FY2018, FY2020, FY2024, FY2025). The 12-year average FCF margin is 4.5%.

Cash-flow distortion table

---

4. Balance Sheet and Financial Resilience

If the cash-flow story is the bear case, the balance sheet is the bull case.

Three points stand out:

1. The deleveraging in FY2021 was decisive. Borrowings dropped from ₹1,559 Cr (FY2020) to ₹37 Cr (FY2021) — likely a one-time settlement using the fertilizer-subsidy back-payment that the Government of India released that year. Borrowings have stayed essentially zero ever since (₹2 Cr at FY2025 close).
2. The investment book is huge. ₹5,055 Cr at FY2025 close is 72% of the current ₹7,011 Cr market cap. A meaningful share is cross-holdings in other Gujarat State PSUs (notably GNFC), so it is not all "deployable cash" — but interest, dividend, and MTM income from this book is what holds up reported net income.
3. Equity book has compounded from ₹4,223 Cr (FY2014) to ₹12,139 Cr (FY2025) — a ~9.6% CAGR. Per-share book value is ₹303 (40 Cr shares of ₹2 face). The stock at ₹176 trades at 0.58x book.

Liquidity & resilience scorecard

Interest coverage = EBIT / interest expense. Anything above 4× is investment-grade comfortable; above 10× is essentially unleveraged. GSFC sits near 80×, which is what you would expect from a debt-free balance sheet.

Working capital tells a more nuanced story than the headline. Debtor days collapsed from a peak of 197 (FY2016) to ~20 (FY2022 onwards) — the subsidy mechanism is much faster now than it was before the Direct Benefit Transfer (DBT) regime. But total working-capital days have crept back up from 84 (FY2024) to 93 (FY2025), with inventory days rising to 89 — the visible cause of the FY2025 cash drag. Watch this in the next four quarters: a return toward 80–85 days would release ₹150–250 Cr of cash.

---

5. Returns, Reinvestment, and Capital Allocation

If you only look at one chart in this section, look at this one.

ROCE (Return on Capital Employed) = EBIT / (debt + equity). It measures pre-tax operating return on every rupee of capital the business uses. India's risk-free rate sits around 7%; 12–15% is industry-average for Indian chemicals; 20%+ is best-in-class.

GSFC's mid-cycle ROCE is 8–9% — barely above the Indian risk-free rate. The peaks (FY2022–23 at 13%) were genuine cycle highs. The current 6% is a cycle trough. This is the key reason the stock trades below book value. Coromandel and Chambal earn 22–27% ROCE; Paradeep earns 14%. GSFC sits at the bottom of the peer group.

Capital allocation: dividend-only, no buyback, no dilution

Capital allocation is mechanical: pay out 20–35% of reported earnings as dividend (with a 50% kicker in the FY2023 peak year), no buybacks, no equity issuance. Equity capital has been frozen at ₹80 Cr (40 Cr shares × ₹2 face) for the entire 12-year period. Per-share book value has therefore tracked retained earnings — ₹105 (FY2014) → ₹303 (FY2025), a 9.7% CAGR.

What management is not doing is also telling. With ₹5,053 Cr of net cash + investments — 72% of market cap — and the stock at 0.58× book, a value-maximising private operator would be running a tender offer at, say, ₹220 to retire 10% of float at a discount. That GSFC does not do this is the PSU governance signal — capital is owned by the Gujarat State and tactically immobile. The investment book is functionally permanent.

Book value compounds; EPS is volatile; FCF per share is the worst of the three. Cumulative FCF per share over the 12-year period is ~₹80 — versus ~₹197 of book-value growth and ~₹162 of cumulative EPS. The "missing" ~₹120 of value sits in the investment portfolio and the working-capital build, not in the operating business.

---

6. Segment and Unit Economics

GSFC reports two segments — Fertilizers and Industrial Products — but a clean machine-readable segmentation series was not available in this run's data set; the segment file came back unpopulated. Based on company disclosures, the FY2024–25 mix is approximately 60–65% fertilizers / 35–40% industrial products by revenue, but operating profit mix is much more skewed toward industrial products in upcycles (caprolactam–nylon-6 was responsible for the FY2022–23 margin spike). Fertilizers earn a regulated, low-teens-of-EBIT-margin spread; industrial products swing from low single-digit margins in trough years to mid-20% margins at the peak.

The investor takeaway without segment data is to treat the caprolactam–nylon spread and benzene/ammonia input costs as the single most important external variable for GSFC's margin direction. Fertilizer volumes are stable; industrial chemicals are the lever.

Note: a refresh of the segment data set (or segment narrative pulled from the FY2025 annual report) is the first thing to add to this page on the next iteration.

---

7. Valuation and Market Expectations

The reader needs to hold three numbers in mind: ₹176 share price, ₹303 book value per share, ₹17.38 trailing EPS.

P/B (Price-to-Book) = market cap / shareholders' equity. Below 1× usually means the market expects future returns on equity to fall short of the cost of equity. EV/EBITDA = (market cap + debt − cash) / EBITDA, a leverage-neutral way to compare cash earning power to enterprise value.

The cleanest valuation lens is enterprise value stripped of the investment book:

• Market cap ₹7,011 Cr
• Plus borrowings ₹2 Cr
• Minus investments ₹5,055 Cr (treating the cross-holdings + financial portfolio as a separable asset)
• = Ex-cash EV ≈ ₹1,958 Cr

Against TTM EBITDA of ~₹984 Cr (operating profit ₹787 Cr + depreciation ₹197 Cr), that is EV/EBITDA of ~2.0× on the operating business, while the headline market-cap-to-EBITDA on the consolidated entity is ~7.1×. Either way, GSFC trades at a structural discount to fertilizer/chemicals peers (Coromandel ~17× P/EBITDA, Chambal ~7×, Paradeep ~9×).

The 10-year P/E range has been 4.5–23×. The current 10× is roughly mid-band. Importantly, the FY2023 trough of 4.5× was at peak earnings (the market was pricing a normalisation, correctly). The current 10× sits on slightly-below-mid-cycle earnings, so it is not as cheap as it looks.

Bear / base / bull triangulation

The valuation argument is asymmetric only if the business returns to mid-cycle. Today's 10× P/E with single-digit ROCE and negative FCF does not imply skewed upside on its own. The thesis depends on either (a) chemical-cycle margin recovery, or (b) capital-allocation reform (special dividend, monetisation of cross-holdings), or (c) both.

---

8. Peer Financial Comparison

The cleanest way to read this table is to look at columns 4 and 7: ROCE and P/B. They tell you what the market is pricing.

The peer set splits into three buckets:

• Quality compounders (Coromandel, Chambal): 22–27% ROCE, 17–20% ROE, trading at 1.9–4.5× book. Their margins are wider, asset turns higher, and capital allocation visibly active. The market correctly pays up.
• Asset-rich, return-poor PSUs (GSFC, GNFC, RCF): single-digit ROCE/ROE, trading below or near book (0.58–1.47×). Govt-of-Gujarat / Govt-of-India ownership constrains capital action. GSFC is the cheapest-on-book in the group, GNFC is second.
• Special situation (FACT, Paradeep): FACT's headline P/E is meaningless after a debt-equity restructuring; Paradeep is recently listed and recovering.

GSFC's P/B of 0.58× is the lowest in the peer set, which is the strongest argument for the stock. But the ROCE of 6.2% is also among the lowest, which is why the discount exists. The peer gap that matters is GSFC vs Chambal: Chambal earns 4.3× the ROCE for 3.2× the P/B. On a return-adjusted basis, Chambal is actually the better value. GSFC needs operating performance to close the gap, not just multiple expansion.

---

9. What to Watch in the Financials

What the financials confirm, contradict, and the next thing to watch

The financials confirm that GSFC is a low-leverage, asset-rich, dividend-paying PSU with a deeply cyclical operating business and a real ₹303-per-share book that has compounded steadily. They contradict the easy "cheap on P/E and P/B" narrative — because (a) earnings have not turned into cash for two years, (b) ROCE is durably single-digit, and (c) the investment book that makes the balance sheet look great is functionally locked up by PSU governance. The stock trades at 0.58× book for valid reasons, not despite them.

What changes the view next? Watch operating cash flow. Two consecutive quarters of CFO above ₹300 Cr each — meaning the working-capital build reverses — would argue that the FY2024–25 cash drain was a transitory subsidy/inventory issue rather than structural, and would support a re-rating of P/E and P/B toward the peer average. If CFO stays sub-₹200 Cr per quarter through FY2026, the equity story is "yield + book-value floor" only, and the multiple stays where it is.

The first financial metric to watch is operating cash flow (CFO) — specifically, whether the next two quarterly statements show CFO returning to ₹300 Cr+ per quarter on the back of a working-capital release.